Baolingbao Biology Co Ltd
Baolingbao Biology Co.,Ltd. researches and develops, manufactures, and sells a range of functional sugars in China. The company offers prebiotics, such as isomaltooligosaccharides, galactooligosaccharides, fructooligosaccharides, bagasse trisaccharides, and xylooligosaccharides; sugar alcohols and new sugar source products, including erythritol, trehalose, crystalline fructose, alodonose, and mal… Read more
Baolingbao Biology Co Ltd (002286) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.061x
Based on the latest financial reports, Baolingbao Biology Co Ltd (002286) has a cash flow conversion efficiency ratio of 0.061x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥134.96 Million) by net assets (CN¥2.20 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Baolingbao Biology Co Ltd - Cash Flow Conversion Efficiency Trend (2006–2024)
This chart illustrates how Baolingbao Biology Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Baolingbao Biology Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Baolingbao Biology Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hangzhou Huawang New Material Technology Co.Ltd.
SHG:605377
|
0.026x |
|
Hinova Pharmaceuticals Inc. A
SHG:688302
|
N/A |
|
Carter Bank and Trust
NASDAQ:CARE
|
0.028x |
|
ZheJiang RIFA Digital Precision Machinery Co Ltd
SHE:002520
|
0.384x |
|
Tanzanian Royalty Exploration Corp
NYSE MKT:TRX
|
0.039x |
|
Vitesco Technologies Group Aktiengesellschaft
PINK:VTSCY
|
-0.072x |
|
Kunshan Top A Intelligent Equipment
SHE:300836
|
-0.017x |
|
Replimune Group Inc
NASDAQ:REPL
|
-0.313x |
Annual Cash Flow Conversion Efficiency for Baolingbao Biology Co Ltd (2006–2024)
The table below shows the annual cash flow conversion efficiency of Baolingbao Biology Co Ltd from 2006 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥2.04 Billion | CN¥248.72 Million | 0.122x | -14.39% |
| 2023-12-31 | CN¥1.98 Billion | CN¥282.28 Million | 0.142x | +825.49% |
| 2022-12-31 | CN¥2.00 Billion | CN¥30.82 Million | 0.015x | -86.48% |
| 2021-12-31 | CN¥1.81 Billion | CN¥206.27 Million | 0.114x | -54.34% |
| 2020-12-31 | CN¥1.60 Billion | CN¥398.46 Million | 0.249x | +153.58% |
| 2019-12-31 | CN¥1.57 Billion | CN¥153.95 Million | 0.098x | +13.86% |
| 2018-12-31 | CN¥1.54 Billion | CN¥133.05 Million | 0.086x | +456.56% |
| 2017-12-31 | CN¥1.53 Billion | CN¥-36.91 Million | -0.024x | -133.49% |
| 2016-12-31 | CN¥1.51 Billion | CN¥108.98 Million | 0.072x | +37.85% |
| 2015-12-31 | CN¥1.48 Billion | CN¥77.49 Million | 0.052x | -25.34% |
| 2014-12-31 | CN¥1.45 Billion | CN¥101.77 Million | 0.070x | +17.74% |
| 2013-12-31 | CN¥1.44 Billion | CN¥85.60 Million | 0.060x | -48.22% |
| 2012-12-31 | CN¥817.45 Million | CN¥94.15 Million | 0.115x | -48.98% |
| 2011-12-31 | CN¥760.53 Million | CN¥171.70 Million | 0.226x | +478.31% |
| 2010-12-31 | CN¥703.11 Million | CN¥27.45 Million | 0.039x | -41.88% |
| 2009-12-31 | CN¥662.61 Million | CN¥44.51 Million | 0.067x | -85.56% |
| 2008-12-31 | CN¥238.05 Million | CN¥110.77 Million | 0.465x | +13.88% |
| 2007-12-31 | CN¥193.28 Million | CN¥78.98 Million | 0.409x | +140.46% |
| 2006-12-31 | CN¥112.53 Million | CN¥19.12 Million | 0.170x | -- |